Assay Detects Urinary Proteins in Bladder Cancer
|
By LabMedica International staff writers Posted on 08 Jul 2013 |
|
Image: Synergy HT Multi-Mode microplate reader (Photo courtesy of Biotek).
A high-throughput assay has been developed for the detection of tyrosine-phosphorylated proteins (TPPs) in urine of bladder cancer patients.
Urinary TPPs appear to be a potential cancer marker for the detection of early stages of bladder cancer, but the development of methods to perform the evaluation of their diagnostic performances and their clinical validation is crucial.
Oncologists at the University of Turin Medical School (Turin, Italy) collected urine specimens from 23 bladder cancer patients and 43 healthy volunteers. There were 19 males and 4 females with bladder cancer with a mean age of 67.65 ± 10.63. The scientists developed an immobilized metal affinity chromatography (IMAC) system that was miniaturized in a 96 well format. Luminescence, visible, and infrared fluorescence antibody-based detection methods were comparatively evaluated.
The luminescence end-point detection was performed by means of a Synergy HT Multi-Mode microplate reader (Biotek; Winooski, VT, USA) and infrared (IR) fluorescence detection was performed with the Odyssey Infrared Imaging System (LI-COR Biosciences; Lincoln, NE, USA). Due to their low abundance, both a phosphoprotein enrichment step and very sensitive detection methods are required to detect TPPs in urine samples. To pursue high throughput, reproducibility and cost containment, which are required for bladder cancer screening programs. The scientists coupled the preanalytical IMAC procedure with high sensitive detection phases using either infrared fluorescence or chemiluminescence in an automated platform.
The assay represents the first quantitative and high throughput method for the measurement of TPPs in urine. Preliminary evaluation of the sensitivity and the specificity was 87% and 95% respectively, which confirmed the excellent diagnostic performances of TPPs as bladder cancer marker. The authors concluded that their method had optimized the measurement of TPP levels in urine samples, integrating the preanalytical and analytical phases in a 96 well format and with the use of affordable detection methods. This method is now feasible to be applied to a large number of patients and high-risk subjects to establish its actual diagnostic and predictive power. The study was published in the June 2013 issue of the journal Biochimica et Biophysica Acta.
Related Links:
University of Turin Medical School
Biotek
LI-COR Biosciences
Urinary TPPs appear to be a potential cancer marker for the detection of early stages of bladder cancer, but the development of methods to perform the evaluation of their diagnostic performances and their clinical validation is crucial.
Oncologists at the University of Turin Medical School (Turin, Italy) collected urine specimens from 23 bladder cancer patients and 43 healthy volunteers. There were 19 males and 4 females with bladder cancer with a mean age of 67.65 ± 10.63. The scientists developed an immobilized metal affinity chromatography (IMAC) system that was miniaturized in a 96 well format. Luminescence, visible, and infrared fluorescence antibody-based detection methods were comparatively evaluated.
The luminescence end-point detection was performed by means of a Synergy HT Multi-Mode microplate reader (Biotek; Winooski, VT, USA) and infrared (IR) fluorescence detection was performed with the Odyssey Infrared Imaging System (LI-COR Biosciences; Lincoln, NE, USA). Due to their low abundance, both a phosphoprotein enrichment step and very sensitive detection methods are required to detect TPPs in urine samples. To pursue high throughput, reproducibility and cost containment, which are required for bladder cancer screening programs. The scientists coupled the preanalytical IMAC procedure with high sensitive detection phases using either infrared fluorescence or chemiluminescence in an automated platform.
The assay represents the first quantitative and high throughput method for the measurement of TPPs in urine. Preliminary evaluation of the sensitivity and the specificity was 87% and 95% respectively, which confirmed the excellent diagnostic performances of TPPs as bladder cancer marker. The authors concluded that their method had optimized the measurement of TPP levels in urine samples, integrating the preanalytical and analytical phases in a 96 well format and with the use of affordable detection methods. This method is now feasible to be applied to a large number of patients and high-risk subjects to establish its actual diagnostic and predictive power. The study was published in the June 2013 issue of the journal Biochimica et Biophysica Acta.
Related Links:
University of Turin Medical School
Biotek
LI-COR Biosciences
New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
New
TORCH Infections Test
TORCH Panel
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels
Latest Clinical Chem. News
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
Channels
Molecular Diagnostics
view channel
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
